3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Small Cell Lung Carcinoma
30
Burkitt Lymphoma
12
Lung Neoplasms
11
Leukemia, Myeloid, Acute
11
Recurrence
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma
10
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
8
Lymphoma, Large B-Cell, Diffuse
8
Lymphoma, Non-Hodgkin
7
Hodgkin Disease
7
Carcinoma, Non-Small-Cell Lung
7
Neuroblastoma
4
Lymphoma, B-Cell
4
Leukemia
4
Wilms Tumor
3
Sarcoma, Ewing
3
Plasmablastic Lymphoma
3
Neoplasms, Germ Cell and Embryonal
3
Neoplasms
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, T-Cell
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Immunoblastic Lymphadenopathy
3
Ganglioneuroblastoma
3
Teratoma
2
Sarcoma
2
Interventions
X-Rays
7
Phantoms, Imaging
7
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
Nuclear Medicine Department, Hospital
5
Biopsy
5
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Vincristine
2
Temozolomide
2
LY3023414
2
Fluorouracil
2
Doxorubicin
2
Cisplatin
2
Carboplatin
2
talazoparib
1
sodium thiosulfate
1
pembrolizumab
1
olaparib
1
irinotecan sucrosofate
1
fludarabine phosphate
1
fludarabine
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hepatoblastoma
×
Etoposide
×
90 days
×
Clear all
NCT03017326
2026-05-13
PHITT
University of Birmingham
Phase 3
Active not recruiting
450 enrolled